Top 3 Health Care Stocks You May Want To Dump This Quarter
Top 3 Health Care Stocks You May Want To Dump This Quarter
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年7月30日，医疗保健行业的三支股票可能对那些将动量视为交易决策关键标准的投资者发出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一种动量指标，它将股票在股价上升的日子里的强度与在股价下跌的日子里的强度进行比较。与股票价格的走势相比，它可以让交易员更好地了解股票在短期内的表现。当RSI高于70时，资产通常被认为是超买的，据Benzinga Pro称。
Here's the latest list of major overbought players in this sector.
以下是行业中超买的主要股票列表。
Verona Pharma PLC – ADR (NASDAQ:VRNA)
维罗纳制药PLC-ADR（纳斯达克股票代码：VRNA）
- Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a 52-week high of $23.72.
- RSI Value: 71.29
- VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday.
- 维罗纳制药将于8月8日（星期四）公布其第二季度的财务业绩。公司股票在过去一个月中上涨了约46％，并且创下了52周高位23.72美元。
- RSI值：71.29
- VRNA价格走势：维罗纳制药股票周一下跌0.5％，报22.61美元。
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)
Catalyst Pharmaceuticals公司（纳斯达克股票代码：CPRX）
- On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE in Canada. "We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product's footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care," stated Richard J. Daly, CEO and President of Catalyst. The company's stock gained around 11% over the past month and has a 52-week high of $17.99.
- RSI Value: 70.99
- CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday.
- 7月24日，Catalyst Pharmaceuticals公司与Kye Pharmaceuticals公司签订了一项独家授权，供应和商业化协议，旨在向加拿大推销AGAMREE。 Catalyst的首席执行官兼总裁Richard J. Daly表示：“我们很高兴与Kye Pharmaceuticals公司就AGAMREE签订这项协议，在我们的战略扩大产品在北美的销售范围方面迈出了关键一步。这项合作利用我们的共同专业知识，通过授权我们的第二种治疗罕见疾病产品进入加拿大，加强了我们的联盟，并展示了我们对患者护理的持续承诺。”该公司的股票在过去一个月中上涨了约11％，并且创下了52周高位17.99美元。
- RSI值：70.99
- CPRX价格走势：Catalyst Pharmaceuticals公司股票周一下跌0.6％，报17.48美元。
Viridian Therapeutics Inc (NASDAQ:VRDN)
Viridian Therapeutics公司（纳斯达克股票代码：VRDN）
- On July 29, Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42. The company's stock gained around 31% over the past month and has a 52-week high of $24.18.
- RSI Value: 73.86
- VRDN Price Action: Shares of Viridian Therapeutics gained 3.8% to close at $17.29 on Monday.
- 7月29日，Wedbush维持对该股票的跑赢大盘评级，并重申其42美元的目标价。该公司的股票在过去一个月中上涨了约31％，并且创下了52周高位24.18美元。
- RSI值：73.86
- VRDN价格走势：Viridian Therapeutics公司股票周一上涨3.8％，报17.29美元。
- Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling
- Roblox、摩根士丹利和其他两只股票的内部人士正在抛售。